EUVIMEDSkopri EUVIMED
LeserbriefKommentarSystematische Übersicht

The systematic review and meta‐analysis of cytisine

Kamran Siddiqi iD, Omara Dogar iD, Rhian Gabe, Aziz Sheikh

Addiction · 2024

DOI: 10.1111/add.16441 ↗

At a glance

Leserbrief in Addiction, 2024. Written by Kamran Siddiqi and 3 co-authors. Institution: Department of Health Sciences, University of York, York, UK. Major MEDLINE topics: Alkaloids, Azocines, Quinolizidine Alkaloids, Quinolizines. Cited 1 times so far (Crossref); 4 references.

AstrattSubjectsDettalji biblijografiċiCiteRelated studies

Abstract (original language)

We welcome the systematic review and meta-analysis by De Santi et al. on the effectiveness of cytisine in smoking cessation [1]. We congratulate the authors for their commendable effort in consolidating the existing literature on cytisine—a smoking cessation medication that has, regrettably, not received the attention commensurate with its potential, particularly when juxtaposed with alternative medications that are both scarce and costly. The timeliness of this review is underscored by the increasing number of jurisdictions allowing cytisine’s use in treating smoking cessation [2]. Notably, in the United Kingdom (UK), cytisine is set to become available this year, although it received licensing approval from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) in 2019 [3]. While we acknowledge the thoroughness of the authors’ methods, which transparently delineate inclusion and exclusion criteria and employ the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system for risk of bias assessment, we have concerns regarding the application of these methods in selecting studies for their analyses. The discrepancy arises in the sensitivity analysis, which ostensibly restricts inclusion based on the risk of bias. Our key concern relates to the exclusion of the study conducted by Dogar et al. [4], the largest trial included in the systematic review, with the authors assigning it a low risk of bias (their Fig. 2) [1]. However, in the sensitivity analysis (their Fig. 5), where only five trials were included, Dogar et al. was excluded due to purportedly ‘having a high risk of bias’. This is contradictory to the authors’ earlier classification in their Fig. 2. We must disclose our interest in this matter as the investigators behind the study reported in Dogar et al. [4]. The authors further justified the exclusion by noting in the discussion section that Dogar et al. conducted their trial on tuberculosis (TB) patients, unlike other trials that involved different participant demographics. While this is true, the inclusion criteria did not specifically exclude trials with TB patients. Moreover, the authors suggested that the small effect size observed in Dogar et al. could be attributed to low adherence to cytisine but failed to present any evidence to substantiate this assertion. We wonder if the adherence to cytisine and the methods used to measure it were compared across the trials included in the review. Upon employing the authors’ PROSPERO registration (https://www.crd.york.ac.uk/PROSPERO/display_record.php?RecordID=296780) and their stated methods, we find the exclusion of Dogar et al. [4] from the sensitivity analysis unjustified. Kamran Siddiqi: Conceptualization (equal); writing—original draft (equal); writing—review and editing (equal). Omara Dogar: Conceptualization (equal); writing—review and editing (equal). Rhian Gabe: Conceptualization (equal); writing—review and editing (equal). Aziz Sheikh: Conceptualization (equal); writing—review and editing (equal). No funding was received. We are all investigators and authors of one of the studies [4] included in the review.

Subjects

MeSH terms (MEDLINE)

AlkaloidsAzocinesQuinolizidine AlkaloidsQuinolizinesHumansDrugs, Chinese HerbalSmoking CessationSmoking Cessation AgentsMeta-Analysis as TopicSystematic Reviews as Topic

Author keywords

Cytisinemeta‐analysissmoking cessationsmoking cessation medicationsystematic reviewtobacco

Substances

AlkaloidsAzocinescytisineDrugs, Chinese HerbalQuinolizidine AlkaloidsQuinolizinesSmoking Cessation Agents

Authors and institutions

  • Department of Health Sciences, University of York, York, UK.
  • Wolfson Institute of Population Health, Queen Mary University London, London, UK.
  • Usher Institute, The University of Edinburgh, Old Medical School, Edinburgh, UK.

ORCID profiles: Kamran Siddiqi, Omara Dogar

Cite

APA

Siddiqi, K., Dogar, O., Gabe, R., & Sheikh, A. (2024). The systematic review and meta‐analysis of cytisine. Addiction. https://doi.org/10.1111/add.16441

Vancouver

Siddiqi K, Dogar O, Gabe R, Sheikh A. The systematic review and meta‐analysis of cytisine. Addiction. 2024. doi:10.1111/add.16441

BibTeX
@article{Siddiqi2024,
  author = {Siddiqi, Kamran and Dogar, Omara and Gabe, Rhian and Sheikh, Aziz},
  title = {The systematic review and meta‐analysis of cytisine},
  journal = {Addiction},
  year = {2024},
  doi = {10.1111/add.16441}
}
Start for free →